Mitsubishi UFJ Trust & Banking Corp Reduces Position in Kenvue Inc. $KVUE

Mitsubishi UFJ Trust & Banking Corp trimmed its position in Kenvue Inc. (NYSE:KVUE) by 3.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 795,402 shares of the company’s stock after selling 29,505 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp’s holdings in Kenvue were worth $12,909,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Renaissance Capital LLC increased its stake in Kenvue by 8.3% in the second quarter. Renaissance Capital LLC now owns 629,177 shares of the company’s stock valued at $13,169,000 after purchasing an additional 48,267 shares during the last quarter. Cornell Pochily Investment Advisors Inc. boosted its holdings in shares of Kenvue by 144.6% in the 2nd quarter. Cornell Pochily Investment Advisors Inc. now owns 33,173 shares of the company’s stock valued at $694,000 after buying an additional 19,609 shares in the last quarter. TrueMark Investments LLC boosted its holdings in shares of Kenvue by 8.8% in the 2nd quarter. TrueMark Investments LLC now owns 229,648 shares of the company’s stock valued at $4,807,000 after buying an additional 18,623 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Kenvue by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 233,246,267 shares of the company’s stock valued at $4,881,844,000 after buying an additional 4,101,880 shares during the last quarter. Finally, OFI Invest Asset Management raised its stake in Kenvue by 705.6% during the 2nd quarter. OFI Invest Asset Management now owns 26,979 shares of the company’s stock worth $565,000 after acquiring an additional 23,630 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Down 0.8%

KVUE stock opened at $17.50 on Wednesday. Kenvue Inc. has a one year low of $14.02 and a one year high of $25.17. The stock has a market capitalization of $33.52 billion, a PE ratio of 23.33 and a beta of 0.60. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 0.98. The company has a fifty day moving average of $17.10 and a 200-day moving average of $18.08.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Monday, November 3rd. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The company had revenue of $3.76 billion for the quarter, compared to analyst estimates of $3.83 billion. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The firm’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.28 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Insider Transactions at Kenvue

In other Kenvue news, Director Jeffrey C. Smith bought 3,200,000 shares of Kenvue stock in a transaction on Friday, December 12th. The stock was bought at an average price of $17.37 per share, with a total value of $55,584,000.00. Following the completion of the acquisition, the director owned 27,307,632 shares in the company, valued at $474,333,567.84. The trade was a 13.27% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.17% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on KVUE. Weiss Ratings restated a “hold (c-)” rating on shares of Kenvue in a research note on Friday, January 9th. Canaccord Genuity Group reissued a “hold” rating and issued a $15.00 target price (down from $26.00) on shares of Kenvue in a report on Wednesday, October 29th. Deutsche Bank Aktiengesellschaft set a $18.00 target price on Kenvue in a research report on Friday, October 24th. Jefferies Financial Group cut their price target on Kenvue from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Monday, October 27th. Finally, Barclays increased their price objective on Kenvue from $17.00 to $18.00 and gave the company an “equal weight” rating in a report on Monday, November 10th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and twelve have assigned a Hold rating to the stock. According to MarketBeat.com, Kenvue presently has an average rating of “Hold” and an average target price of $20.23.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.